A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

The build vs. outsource decision is strategic. Building in-house is justified when manufacturing is a core competitive advantage or the process itself is your key IP. Otherwise, outsourcing to a CDMO offers critical speed to clinic and preserves capital.

Syndax bypasses the lengthy initial lab phase by in-licensing promising science from external sources. This allows their internal experts to focus directly on clinical development in areas of high unmet medical need, a key strategy behind getting two drug approvals in two years.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

To avoid common gene therapy manufacturing delays, Ray Therapeutics invested heavily in its Chemistry, Manufacturing, and Controls (CMC) process early. They established a commercial-scale process *before* dosing a single patient, eliminating the risky and time-consuming transition from clinical to commercial material.

Ona Therapeutics maintains a small team by following a simple rule: outsource functions that external experts can do better (like CROs and manufacturing) at a reasonable price. This allows them to focus all internal resources on their core, specialized competency of designing novel molecules and advancing their pipeline.

The primary driver for outsourcing in the pharmaceutical industry is no longer just a need for more manufacturing capacity. It has strategically shifted towards seeking specialized expertise and partnerships, particularly in complex areas like CMC (Chemistry, Manufacturing, and Controls) where the process defines the product.

To leverage modern, faster FDA pathways for biosimilars, robust analytical data demonstrating biosimilarity is critical. Therefore, a startup's choice of a Contract Development and Manufacturing Organization (CDMO) should hinge on their analytical expertise, which can reduce or eliminate the need for lengthy clinical trials.